BioSpace News Archive

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation

Healthcare executive Michael Rawlings has been appointed Senior Vice President of Facilities, Construction and Support Services by Hospital for Special Surgery.

These funds will be used to advance the development of the Company’s COVID-19 saliva-based rapid antigen test, SCV2, and for general working capital.

Orlando, Florida--(Newsfile Corp. - January 29, 2021) - Aqua Power Systems Inc. (OTC Pink: APSI) announced today that Stephen Carnes has recently been appointed as President and CEO of the Company.

Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

Health Canada testing confirmed that Bio Life hand sanitizer by Bio Life Sciences Corp. / 10932540 Canada Inc. contains methanol, which may cause serious health issues, especially if ingested.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors

Spero Therapeutics, Inc. announced that on January 29, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,300 shares of its common stock to six new employees under the Spero Therapeutics, Inc.

DW Healthcare Partners V, L.P. (“DWHP”), announced today the expiration and final results of its previously announced cash tender offer (the “Tender Offer”) to purchase all of the outstanding ordinary shares (the “Tender Securities”) of Parnell Pharmaceuticals Holdings Ltd (OTC Pink Open Market: PARNF) (“Parnell”) at a price of U.S.$0.40 per share,

Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the closing of a $9 million follow-on public offering.